Gene

PSMD4

proteasome 26S subunit ubiquitin receptor, non-ATPase 4

Curated evidence

Clinical evidence (2)

CIViC items involving this gene, grouped by molecular profile and therapy, with native levels and directions. 50 items per page.

civicCuratedShowing 1–2 of 2 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
PSMD4 Amplification1
Talazoparib	Malignant Breast Neoplasm	Predictive	D	Supports Sensitivity Response	3	submitted	EID4834 Current randomized Phase III trials of PARPi in metastatic breast cancer are limited to patients with BRCA1/2 mutations, no biomarker of PARPi beyond BRCA status is available. we created a cell line (… (full text at CIViC) PMID 28316110 · Fejzo et al., 2017 · Open in CIViC	civic
PSMD4 Overexpression1
Carfilzomib	Malignant Colorectal NeoplasmCURATED_BROADER	Predictive	D	Supports Sensitivity Response	3	submitted	EID7330 Nrf2 transfected colorectal cancer cells (shNrf2-HCT116) were found to have a 13.6 fold elevation in PSMD4, suggesting cytoplasmic Nrf2 leads to PSMD4 overexpression. Increased HIF-1a and nuclear B-c…

Cohorts

Frequency = cases affected / cases profiled within one cohort. Cohorts are never pooled.

gdcObserved5 cohort rows · frequency = affected / profiled, as published by each cohort; cohorts are not pooled. Hover a row badge for its release.

Cohort	Mapped cancer	Alteration	Affected (n)	Profiled (n)	Frequency (%)	Rank in cohort	Source
CDDP Integrative Analysis of Lung Adenocarcinoma (Phase 2) CDDP_EAGLE-1	Lung Adenocarcinoma

Literature

Data not yet available

No publication linked to this gene yet.